AU645543B2 - Pharmaceuticals - Google Patents

Pharmaceuticals

Info

Publication number
AU645543B2
AU645543B2 AU73362/91A AU7336291A AU645543B2 AU 645543 B2 AU645543 B2 AU 645543B2 AU 73362/91 A AU73362/91 A AU 73362/91A AU 7336291 A AU7336291 A AU 7336291A AU 645543 B2 AU645543 B2 AU 645543B2
Authority
AU
Australia
Prior art keywords
ammonium sulphate
solution
formula
tris buffer
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU73362/91A
Other versions
AU7336291A (en
Inventor
Trevor John Grinter
John Thomas Sime
Stefan Roland Woroniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of AU7336291A publication Critical patent/AU7336291A/en
Application granted granted Critical
Publication of AU645543B2 publication Critical patent/AU645543B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/02Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/62Carboxylic acid esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

PHARMACEUTICALS
The present invention relates to a process for the preparation of an intermediate which is useful in the preparation of compounds having antiviral activity.
EP-A-141927 (Beecham Group p.I.e.) describes the compound, penciclovir and its use as an antiviral agent and EP-A-182024 (Beecham Group p.I.e.) describes its pro-drug, famciclovir. Penciclovir and famciclovir are of formulae (A) and (B) respectively:
HO - CH„ - CH - CH0 - OH
(A)
(B)
The method of preparation of the above compounds involves the reaction of 2-amino-6-chloropurine of formula (C) :
with a side-chain intermediate of formula (D)
Q
(D)
wherein Q is a leaving group, such as hydroxy or halo, for example iodo or bromo.
The side-chain intermediate of formula (D) is not readily available and is prepared by a multi-stage synthesis. Although the compound of formula (D) but wherein Q is replaced by acetate i.e. of formula (I) :
can be prepared from commercially available triethyl 1,1,2-ethanetricarboxylate by a modification of the method of .J. Bailey et.. .al., J. Org. Chem., 1962, it is not possible to selectively convert one of the acetoxy groups to a leaving group, since they are all in a similar chemical environment and chemical hydrolysis is unlikely to differentiate between the functionalities.
A novel process has now been discovered which converts a compound of formula (I) , the triacetate, to the diacetate of formula (II) :
(ID
by using a microbial hydrolase.
Accordingly, the present invention provides a process for the preparation of a compound of formula (II) as hereinbefore defined, which process comprises the treatment of a compound of formula (I) , as hereinbefore defined, with a microbial hydrolase.
Suitable microbial hydrolases are to be found in microorganisms which include Penicillia and Bacteria, in particular Penicillium frequentans IMI 92265.
The organisms are grown in a nutrient broth or other suitable medium at a temperature of 10-50°C, preferably around 20-40°C, according to the nature of the organism employed. The reactions can be carried out in this medium, or in an alternative medium or salt solution after separation and transfer of the cells. Alternatively, purified or partially purified enzymes can be used after cell disruption and fractionation of the cells.
The reaction is carried out at a pH in the range 3-10, preferably 5.0-8.0, usually at a temperature of 10-40°C, or 20-40°C.
The enzyme transformation may be improved in yield in the presence of ammonium sulphate, preferably 1 molar.
Typically, enzyme in cell bound or cell-free form can be immobilised and re-used. In the case of Penicillium frequentans IMl 92265 this can be done several times without significant loss of activity. The substrate concentration may be increased to 1% or greater w/v. Hence a continuous production method can be envisaged, passing the substrate over the immobilised enzyme in a column, loop reactor or similar reactor.
The product is purified by extraction into a suitable solvent following which it may optionally be chromatographed.
The process has the advantage that minimal amounts of by-product of formula (III) are produced.
(III) The following Examples illustrate the invention. It will be appreciated that yields may be improved by carrying out strain improvement on the organism, by known techniques.
Example 1
Culture of Penicillium frequentans IMl 92265
Two loopsful of mycelium from a slope of Penicillium frequentans IMl 92265 were mixed in 4ml of 0.02% Tween 80 in water and 2ml of the suspension was used to inoculate 40ml of seed medium in a 250ml Erlenmeyer flask. The seed medium comprised (% w/v) cornsteep liquor (4%); treacle (2.6%); CaC03 (0.5%) and distillers' solubles (Scotafeed) (2%) in deionised water adjusted to pH 5.2. After shaking at 240rpm at 28<C for 72h, 1.5ml of the seed broth was used to inoculate 40ml of production medium in 250ml Erlenmeyer flasks. This medium comprised (% w/v) glucose (3%), nutrient broth (0.8%); yeast extract (0.2%) and malt extract (0.3%) in deionised water adjusted to pH 5.6. These flasks were incubated, with shaking at 240rpm, at 28°C, for 72h.
Example 2
Reqioselective ester hydrolysis with whole cells of Penicillium frequentans IMl 92265
The triacetate of formula (I) was added to cultured shake flasks of Penicillium frequentans IMl 92265, produced as in example 1, to give a final substrate concentration of 4mg ml- . The flasks were then shaken at 240rpm and 28<C and finally assayed for products after centrifugation and extraction of the supernatant with chloroform. The organic phase was assayed by hplc. After incubation of the substrate with the microorganism for 6hr, a 15% conversion of su,;strate to diacetate product (II) was indicated and the ratio of product (II) to its regioisomer (III) was 91:9. After 9h incubation a 6% conversion to product was indicated and the ratio of product (II) to its regioisomer (III) was 97:3.
Example 3
Extraction and partial purification of a reqioselective esterase from Penicillium frequentans IMl 92265
The mycelium from 1.61 of Penicillium frequentans IMl 92265 culture broth, produced as in example 1, was separated by centrifugation (16,000xg, 10 min., 4°C) after cooling to 4°C. The biomass was resuspended to 650ml in 0.1M Tris buffer at pH 7.5 and the cells disrupted using a French press (1250psi) in 60ml batches of cell slurry. After centrifugation (23,000xg, 20 min., 4°C) the supernatant was adjusted to pH 7.1 by the addition of IM sodium hydroxide solution and a solution of 3.65g of streptomycin sulphate in 5ml water was added with stirring: after 0.5h at 0°C the cell extract was centrifuged (39,000xg, 20 min., 4°C) and the separated supernatant brought to a 60% saturation level of ammonium sulphate by the addition of solid ammonium sulphate while stirring. After 15 min. at 0°C then centrifugation (23,000xg, 10 min., °C) , the separated supernatant was brought to 80% saturation of ammonium sulphate as before. After 15 min. at 0°C re-centrifugation as before and separation of the supernatant left a precipitate which was dissolved in ".5ml 25mM Tris buffer, pH 7.5. This solution was desalted on Sephadex PD10 columns according to the manufacturers instructions eluting with 25mM Tris buffer, pH 7.5. The desalted protein preparation was made up to 20ml volume with deionised water and applied to an anion exchange resin. column (DEAE-Trisacryl, 7.5 x " .8cm) which had been pre-equilibrated with 25mM Tris buffer, pH 7.5. Elution was with this buffer and, over 8h, a linear gradient of 0 - 300mM ammonium sulphate solution in the same buffer.
Column fractions were assayed for esterase activity by incubating 250μl of column protein fraction with 250μl of a 4mg ml-1 solution of triacetate (I) in 0.2M Tris buffer pH 7.5 with 0.4M ammonium sulphate. After 18h at ambient temperature the solution was extracted with 125μl chloroform which was assayed by hplc. Two protein fractions were isolated which showed 80% conversion of (I) to the product
(II) and neither showed more than 11% of the regioisomer
(III) in the mixture of diacetate (II) and (III) . Column protein fractions were optionally concentrated by ultrafiltration and the protein concentrations determined (Method of M.M. Bradford, Anal. Biochem., 1974, 72., 248-254) .
Example 4
Reqioselective ester hydrolysis with enzyme preparation from Penicillium frequentans IMl 92665
To 125μl of a 4mg ml-1 solution of triacetate (I) in 1.2M Tris buffer pH 7.5 was added 250μl of an enzyme preparation described in example 3 with a protein concentration of 2.67 mg ml-1, and 125 μl of 4M ammonium sulphate solution in 12mM Tris buffer pH 7.5. After gentle mixing the reactions were incubated at 20°C for 4h then the products extracted into 125μl chloroform and assayed by hplc. A conversion of 97% substrate (I) to diacetate (II) was found and the ratio of product (II) to its regioisomer (III) was 95:5. Example 5
Effect of ammonium sulphate on enzyme catalysed ester hydrolysis
An esterase preparation was obtained by the procedure described in example 3 with a protein concentration of 3.56mg ml . A 250μl aliquot of this was added to each of two mixtures of 5mg of triacetate (I) in 125μl of 4M ammonium sulphate solution in 12mM Tris buffer pH 7.5 and to the other reaction was added 125μl 12mM Tris buffer pH 7.5.
After gentle mixing for 19h at 20° the reactions were extracted into 250μl chloroform and the organic phase assayed by hplc. Reaction in the presence of ammonium sulphate showed at 71% conversion of triacetate (I) to diacetate (II) whereas in the absence of ammonium sulphate the conversion was 28%. In the presence of ammonium sulphate the ratio of diacetate (II) to its regioisomer (III) was 94.6 whereas in the absence of ammonium sulphate the ratio was 82:18.
Example 6
Immobilisation of the esterase with cyanogen bromide activated Sepharose
An enzyme preparation with a protein concentration of 1.74mg
1 ml--*- was prepared as m example 3 and 1.25ml of this was mixed with 1.25ml of 'coupling buffer' (solution of 0.1M sodium bicarbonate and 0.5M sodium chloride at pH 8.3) . Chromatography on a Sephadex PD10 column in this solution gave 3.5ml of a solution of enzyme from which the Tris buffer had been removed. This solution was added to 0.6ml of cyanogen bromide activated Sepharose 4B which had been prepared according to the manufacturer's instructions. After mixing for 2h the gel was allowed to settle and the supernatant discarded. To 5 the gel was added 4ml of O.IM glycine in 'coupling buffer' and the suspension mixed for a further 1.5h at ambient temperature. The gel was then washed sequentially with 'coupling buffer', 0.4M acetate buffer at pH 4.0 in 0.5M sodium chloride solution, and 'coupling buffer'. The gel 10 was stored in suspension at 4°C.
Example 7
Repeated use of immobilised regioselective esterase
15
Gel immobilised enzyme was prepared as described in example 6 immobilising 5 mg of protein per ml of gel, and 144 ml of this was washed with an equal volume of O.IM Tris buffer, pH 7.5, containing IM ammonium sulphate. To the gel was added
20 72 ml of 4M ammonium sulphate solution and a solution of 600 mg of triacetate (I) in 72 ml of 0.4M Tris buffer, pH 7.5.
The reaction mixture was shaken at 14°C for 5h before centrifugation and removal of the supernatant. The
25 immobilised enzyme preparation was further washed with 0.IM Tris buffer, pH 7.5, containing IM ammonium sulphate and the combined supernatants extracted into chloroform to yield, after drying and evaporation, 403 mg of a clear oil. This oil was shown to comprise (II) and (III) in a ratio of 94:6 0 respectively.
The immobilised enzyme was resuspended in 0.1M Tris buffer, pH 7.5, containing IM ammonium sulphate and stored at 4°C. The same batch was reused as described above on a further nine occasions giving similar results in each case.
A aliquot of gel immobilised enzyme was used under the above described conditions on sixteen occasions with no detectable reduction in activity or regioselectivity as assayed by hplc.
Example 8
Immobilisation of the esterase with Phenyl Sepharose
To 600μl of solid Phenyl Sepharose CL-4B gel was added 625μl of 4M ammonium sulphate solution and 625μl of 0.4M Tris buffer pH 7.5. To this was added 1.25ml of an enzyme preparation with a protein concentration of 1.74mg l- which was prepared as in example 3. The suspension was mixed gently for 30 min. at ambient temperature, centrifuged and the gel washed twice with 4ml of IM ammonium sulphate in O.IM Tris buffer pH 7.5.

Claims (5)

Claims
1. A process for the preparation of a compound of formula (ID :
(ID
which process comprises the treatment of a compound of formula (I) :
(I)
with a microbial hydrolase.
2. A process according to claim 1 wherein the microbial hydrolase is from a Penicillia or Bacteria.
3. A process according to claim 2 wherein the microbial hydrolase is from a Penicillium frequentans IMl 92265.
4. A process according to any one of claims 1 to 3 wherein the reaction takes place in the presence of ammonium sulphate.
5. A process according to any one of claim 1 to 4 wherein the enzyme is immobilised and reused in a continuous production method.
AU73362/91A 1990-03-01 1991-02-21 Pharmaceuticals Ceased AU645543B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9004647 1990-03-01
GB909004647A GB9004647D0 (en) 1990-03-01 1990-03-01 Pharmaceuticals

Publications (2)

Publication Number Publication Date
AU7336291A AU7336291A (en) 1991-09-18
AU645543B2 true AU645543B2 (en) 1994-01-20

Family

ID=10671861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73362/91A Ceased AU645543B2 (en) 1990-03-01 1991-02-21 Pharmaceuticals

Country Status (10)

Country Link
EP (1) EP0518902A1 (en)
JP (1) JPH05503428A (en)
AU (1) AU645543B2 (en)
CA (1) CA2076628A1 (en)
GB (1) GB9004647D0 (en)
IE (1) IE910667A1 (en)
NZ (1) NZ237234A (en)
PT (1) PT96900A (en)
WO (1) WO1991013162A1 (en)
ZA (1) ZA911435B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003166A1 (en) * 1991-08-01 1993-02-18 Beecham Group Plc Process for the preparation of 2-acetoxy-methyl-1,4-butanediole-1-acetate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485225D1 (en) * 1983-08-18 1991-12-05 Beecham Group Plc ANTIVIRAL GUANINE DERIVATIVES.
EP0182024B1 (en) * 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use

Also Published As

Publication number Publication date
IE910667A1 (en) 1991-09-11
NZ237234A (en) 1992-10-28
AU7336291A (en) 1991-09-18
WO1991013162A1 (en) 1991-09-05
CA2076628A1 (en) 1991-09-02
GB9004647D0 (en) 1990-04-25
PT96900A (en) 1991-10-31
ZA911435B (en) 1992-01-29
JPH05503428A (en) 1993-06-10
EP0518902A1 (en) 1992-12-23

Similar Documents

Publication Publication Date Title
US4414328A (en) Process for the preparation of deacetylcephalosporin C
FR2461753A1 (en) PROCESS FOR THE PREPARATION OF A CEPHALOSPORINE BY FERMENTATION AND MICROORGANISM FOR CARRYING OUT SAID METHOD
AU645543B2 (en) Pharmaceuticals
US5457051A (en) Enantioselective hydrolysis of ketoprofen esters by beauveria bassiana and enzymes derived therefrom
WO2007026860A1 (en) METHOD FOR PRODUCTION OF OPTICALLY ACTIVE α-HYDROXYCARBOXYLIC ACID
WO2007060811A1 (en) Process for production of fucoxanthinol
KR20100043230A (en) Microbial kinetic resolution of ethyl-3,4-epoxybutyrate
WO1993003166A1 (en) Process for the preparation of 2-acetoxy-methyl-1,4-butanediole-1-acetate
US4452897A (en) Method of preparing optically active β-(S)-aminoglutaric acid monoalkyl esters
JP2624296B2 (en) Method for producing γ-halo-β-hydroxybutyrate
US5114850A (en) Methods for preparing acetate esters of diols and polyols using corynebacterium oxydans in substantially aqueous media
KR810000048B1 (en) Process for preparing cephalexin by immobilized enzyme
Kalkote et al. An efficient enzymatic preparation of 4 (S)-hydroxy-1 (R)-acetoxy-cyclopent-2-ene by using new yeast isolate
KR830002916B1 (en) Cephalosporin preparation by fermentation
JP4711367B2 (en) Method for producing optically active amino alcohol derivative
JPH04252189A (en) Production of benzenedicarboxlic monoester or derivative thereof
JP3917723B2 (en) Lactone hydrolase and process for producing the same
JPH0585160B2 (en)
JPH10165195A (en) Production of (s)-4-hydroxy-2-pyrrolidone
JPS5921600B2 (en) Method for producing D(-)-β-hydroxyisobutyric acid
JPH03210192A (en) Biochemical production of (s)-1-ethynyl-2-methyl-2-pentenol
CN1070002A (en) Medicine
JPH0856687A (en) Production of (s)-3-(2-thienylthio)butanoic acid
JPH0731486A (en) Production of optically active dicarboxylic acid
JP2002262895A (en) Method for manufacturing unsaturated fatty acid or its derivative